Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital

Devin N. Patel, Shalini Jha, Lauren E. Howard, Christopher Amling, William J. Aronson, Matthew R. Cooperberg, Christopher J. Kane, Martha K. Terris, Brian F. Chapin, Stephen J. Freedland

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: To evaluate the impact of previous local treatment on survival in men with newly diagnosed metastatic castration-resistant prostate cancer. Methods: We carried out a retrospective study of patients newly diagnosed with metastatic castration-resistant prostate cancer in the year 2000 or later from eight Veterans Affairs Medical Centers. Patients were categorized based on prior local therapy (none, prostatectomy ± radiation or radiation alone). Overall and cancer-specific survival was estimated by the Kaplan–Meier method. Cox proportional hazards regression models were used to test the association between prior local treatment and survival. Results: Of 729 patients, 284 (39%) underwent no local treatment, 176 (24%) underwent radical prostatectomy ± radiation and 269 (37%) underwent radiation alone. On multivariable analysis, men with prior prostatectomy had improved overall (hazard ratio 0.71, P = 0.005) and cancer-specific survival (hazard ratio 0.55, P < 0.001) compared with men with no prior local therapy. This improvement in overall (hazard ratio 0.89, P = 0.219) and cancer-specific survival (hazard ratio 0.87, P = 0.170) was not seen in men with prior radiation alone. After further adjusting for comorbidity with the Charlson Comorbidity Index, patients with prior prostatectomy still had improved overall survival (hazard ratio 0.70, P = 0.003), whereas this was not seen in patients who received prior radiation alone (hazard ratio 0.88, P = 0.185). Conclusions: Independent of patient- and disease-related factors, men with metastatic castration-resistant prostate cancer who had undergone prior radical prostatectomy have improved overall and cancer-specific survival compared with those with no prior local therapy.

Original languageEnglish (US)
JournalInternational Journal of Urology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Cancer Care Facilities
Castration
Prostatic Neoplasms
Survival
Prostatectomy
Radiation
Therapeutics
Comorbidity
Neoplasms
Veterans
Proportional Hazards Models
Retrospective Studies

Keywords

  • local therapy
  • metastatic castration-resistant prostate cancer
  • radiation therapy
  • radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer : Results from Shared Equal Access Regional Cancer Hospital. / Patel, Devin N.; Jha, Shalini; Howard, Lauren E.; Amling, Christopher; Aronson, William J.; Cooperberg, Matthew R.; Kane, Christopher J.; Terris, Martha K.; Chapin, Brian F.; Freedland, Stephen J.

In: International Journal of Urology, 01.01.2018.

Research output: Contribution to journalArticle

Patel, Devin N. ; Jha, Shalini ; Howard, Lauren E. ; Amling, Christopher ; Aronson, William J. ; Cooperberg, Matthew R. ; Kane, Christopher J. ; Terris, Martha K. ; Chapin, Brian F. ; Freedland, Stephen J. / Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer : Results from Shared Equal Access Regional Cancer Hospital. In: International Journal of Urology. 2018.
@article{02879673023840ae8bd1936e65747115,
title = "Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital",
abstract = "Objectives: To evaluate the impact of previous local treatment on survival in men with newly diagnosed metastatic castration-resistant prostate cancer. Methods: We carried out a retrospective study of patients newly diagnosed with metastatic castration-resistant prostate cancer in the year 2000 or later from eight Veterans Affairs Medical Centers. Patients were categorized based on prior local therapy (none, prostatectomy ± radiation or radiation alone). Overall and cancer-specific survival was estimated by the Kaplan–Meier method. Cox proportional hazards regression models were used to test the association between prior local treatment and survival. Results: Of 729 patients, 284 (39{\%}) underwent no local treatment, 176 (24{\%}) underwent radical prostatectomy ± radiation and 269 (37{\%}) underwent radiation alone. On multivariable analysis, men with prior prostatectomy had improved overall (hazard ratio 0.71, P = 0.005) and cancer-specific survival (hazard ratio 0.55, P < 0.001) compared with men with no prior local therapy. This improvement in overall (hazard ratio 0.89, P = 0.219) and cancer-specific survival (hazard ratio 0.87, P = 0.170) was not seen in men with prior radiation alone. After further adjusting for comorbidity with the Charlson Comorbidity Index, patients with prior prostatectomy still had improved overall survival (hazard ratio 0.70, P = 0.003), whereas this was not seen in patients who received prior radiation alone (hazard ratio 0.88, P = 0.185). Conclusions: Independent of patient- and disease-related factors, men with metastatic castration-resistant prostate cancer who had undergone prior radical prostatectomy have improved overall and cancer-specific survival compared with those with no prior local therapy.",
keywords = "local therapy, metastatic castration-resistant prostate cancer, radiation therapy, radical prostatectomy",
author = "Patel, {Devin N.} and Shalini Jha and Howard, {Lauren E.} and Christopher Amling and Aronson, {William J.} and Cooperberg, {Matthew R.} and Kane, {Christopher J.} and Terris, {Martha K.} and Chapin, {Brian F.} and Freedland, {Stephen J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/iju.13806",
language = "English (US)",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer

T2 - Results from Shared Equal Access Regional Cancer Hospital

AU - Patel, Devin N.

AU - Jha, Shalini

AU - Howard, Lauren E.

AU - Amling, Christopher

AU - Aronson, William J.

AU - Cooperberg, Matthew R.

AU - Kane, Christopher J.

AU - Terris, Martha K.

AU - Chapin, Brian F.

AU - Freedland, Stephen J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: To evaluate the impact of previous local treatment on survival in men with newly diagnosed metastatic castration-resistant prostate cancer. Methods: We carried out a retrospective study of patients newly diagnosed with metastatic castration-resistant prostate cancer in the year 2000 or later from eight Veterans Affairs Medical Centers. Patients were categorized based on prior local therapy (none, prostatectomy ± radiation or radiation alone). Overall and cancer-specific survival was estimated by the Kaplan–Meier method. Cox proportional hazards regression models were used to test the association between prior local treatment and survival. Results: Of 729 patients, 284 (39%) underwent no local treatment, 176 (24%) underwent radical prostatectomy ± radiation and 269 (37%) underwent radiation alone. On multivariable analysis, men with prior prostatectomy had improved overall (hazard ratio 0.71, P = 0.005) and cancer-specific survival (hazard ratio 0.55, P < 0.001) compared with men with no prior local therapy. This improvement in overall (hazard ratio 0.89, P = 0.219) and cancer-specific survival (hazard ratio 0.87, P = 0.170) was not seen in men with prior radiation alone. After further adjusting for comorbidity with the Charlson Comorbidity Index, patients with prior prostatectomy still had improved overall survival (hazard ratio 0.70, P = 0.003), whereas this was not seen in patients who received prior radiation alone (hazard ratio 0.88, P = 0.185). Conclusions: Independent of patient- and disease-related factors, men with metastatic castration-resistant prostate cancer who had undergone prior radical prostatectomy have improved overall and cancer-specific survival compared with those with no prior local therapy.

AB - Objectives: To evaluate the impact of previous local treatment on survival in men with newly diagnosed metastatic castration-resistant prostate cancer. Methods: We carried out a retrospective study of patients newly diagnosed with metastatic castration-resistant prostate cancer in the year 2000 or later from eight Veterans Affairs Medical Centers. Patients were categorized based on prior local therapy (none, prostatectomy ± radiation or radiation alone). Overall and cancer-specific survival was estimated by the Kaplan–Meier method. Cox proportional hazards regression models were used to test the association between prior local treatment and survival. Results: Of 729 patients, 284 (39%) underwent no local treatment, 176 (24%) underwent radical prostatectomy ± radiation and 269 (37%) underwent radiation alone. On multivariable analysis, men with prior prostatectomy had improved overall (hazard ratio 0.71, P = 0.005) and cancer-specific survival (hazard ratio 0.55, P < 0.001) compared with men with no prior local therapy. This improvement in overall (hazard ratio 0.89, P = 0.219) and cancer-specific survival (hazard ratio 0.87, P = 0.170) was not seen in men with prior radiation alone. After further adjusting for comorbidity with the Charlson Comorbidity Index, patients with prior prostatectomy still had improved overall survival (hazard ratio 0.70, P = 0.003), whereas this was not seen in patients who received prior radiation alone (hazard ratio 0.88, P = 0.185). Conclusions: Independent of patient- and disease-related factors, men with metastatic castration-resistant prostate cancer who had undergone prior radical prostatectomy have improved overall and cancer-specific survival compared with those with no prior local therapy.

KW - local therapy

KW - metastatic castration-resistant prostate cancer

KW - radiation therapy

KW - radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=85053810803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053810803&partnerID=8YFLogxK

U2 - 10.1111/iju.13806

DO - 10.1111/iju.13806

M3 - Article

C2 - 30253446

AN - SCOPUS:85053810803

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

ER -